Real World Retina: Challenges in the Management of Retinal Diseases - Focus on RVO and nAMD is organized by Healio, Vindico Medical Education.
Release Date: November 30, 2023
Expiration Date: November 29, 2024
Activity Description:
Pinnacle clinical studies utilizing intravitreal anti-vascular endothelial growth factor (VEGF) therapies for the management of retinal diseases have demonstrated significant visual and anatomical improvements. However, translating these promising results into real-world practice does not always result in comparable outcomes to clinical studies due to undertreatment and the loss of patient adherence because of treatment burden. New and emerging therapies with extended durations of action along with the refinement of personalized treatment protocols are helping to address the treatment burden, while baseline factors and imaging techniques that assist with monitoring of therapy response have the potential to optimize visual and anatomical outcomes. In this monograph, experts in the field evaluate the evidence for anti-VEGF treatment outcomes for neovascular age-related macular degeneration (nAMD) and retinal vein occlusion (RVO) in clinical practice, identify prognostic indicators for predicting anti-VEGF therapy outcomes, and assess the latest evidence regarding safety, efficacy, and durability of new therapies for the management of nAMD and RVO.
Learning Objectives:
Upon successful completion of this activity, participants should be better able to:
• Evaluate the evidence for anti-VEGF treatment outcomes in retinal vein occlusion in clinical practice.
• Identify patient factors that can assist in predicting anti-VEGF therapy outcomes in patients with retinal vein occlusion.
• Assess the applicability of recent advances in imaging for monitoring treatment response in patients with retinal vein occlusion.
• Evaluate the evidence for anti-VEGF treatment outcomes in nAMD in clinical practice.
• Identify prognostic indicators for predicting anti-VEGF therapy outcomes in patients with nAMD.
• Assess the latest evidence about new treatments for nAMD, including their safety, efficacy, and durability.